Pretreatment attrition in a comparative treatment outcome study on panic disorder.
Pretreatment attrition in a comparative treatment outcome study on panic disorder.
复制标题
恐慌症比较治疗结果研究中的治疗前磨损。
DOI：
10.1176/ajp.155.1.43
复制
发表时间：
1998
期刊：
影响因子：
--
通讯作者：
Gorman,JM
中科院分区：
文献类型：
--
作者：
Hofmann,SG;Barlow,DH;Papp,LA;Detweiler,MF;Ray,SE;Shear,MK;Woods,SW;Gorman,JM
尽管在治疗过程中的损耗的事实是有据可查的，很少有人知道的因素，影响样本选择之前的研究（“治疗前损耗”）。本研究报告的程度和来源的预处理损耗在两个网站的多中心研究惊恐障碍，比较治疗结果丙咪嗪和认知行为therapy.METHODData收集在两个临床研究网站，1例为药物治疗取向（N=420），1例为心理社会治疗取向（N=208）治疗前损耗的主要来源是参与者拒绝。在这两个研究中心，符合条件的患者最常拒绝参与，因为他们要么不愿意开始丙咪嗪治疗（分别为30.6%和47.4%）或停止目前的药物治疗（22.6%和35.1%，）结论比较治疗结果研究的结果不仅限于符合研究标准的人，而且也限于那些愿意开始治疗的人。药物治疗，并停止目前的药物治疗。(Am J Psychiatry 1998; 155：43-47）
OBJECTIVEWhereas the fact of attrition during the course of treatment is well documented, little is known about the factors that affect sample selection before the beginning of a study (“pretreatment attrition”). The present study reports on the degree and sources of pretreatment attrition at two sites of a multicenter study on panic disorder that compared treatment outcomes for imipramine and cognitive behavior therapy.METHODData were collected at two clinical research sites, one with a pharmacological treatment orientation (N=420) and one with a psychosocial treatment orientation (N=208).RESULTSThe main source of pretreatment attrition was participant refusal. At both research sites, eligible patients most often refused participation because they were either unwilling to start treatment with imipramine (30.6% and 47.4%, respectively) or discontinue their current medication (22.6% and 35.1%, respectively).CONCLUSIONSResults from comparative treatment outcome studies are limited not only to people who meet the study criteria but also to those who are willing to begin a medication treatment and discontinue their current medication. (Am J Psychiatry 1998; 155:43–47)